New Jersey-based Catalent Inc. (NYSE: CTLT) has inked a deal with a subsidiary of Johnson & Johnson (NYSE: JNJ) for large scale manufacturing of J&J’s lead vaccine candidate for COVID-19. The collaboration commits to a joint investment for production at the Catalent Biologics facility in Bloomington. Catalent says it plans to add 300 jobs beginning in July in order to begin 24/7 manufacturing schedules by January.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets on
{{ count_down }}